Xbrane Biopharma AB (publ) announces that Siavash Bashiri will leave his role as COO & Head of Biosimilars

Xbrane Biopharma AB today announces that Siavash Bashiri has informed CEO Martin Åmark of his decision to leave his role as COO & Head of Biosimilars.

Siavash Bashiri has been with the company since 2012 and currently serves as COO & Head of Biosimilars. He will remain in his role until 28 February 2027 to ensure an orderly transition.

"Siavash has been a central part of Xbrane during a significant period of the company's development. His commitment, expertise and drive have made an important contribution to the company's development and to building our biosimilar portfolio. I would like to warmly thank Siavash for his highly valuable contributions over all these years and wish him every success in the future," says Martin Åmark, CEO of Xbrane Biopharma.

"After 14 years at Xbrane, moving on naturally feels significant. I am immensely proud of the journey we have made and of what we have built together. Above all, I am grateful to have had the opportunity to work with so many highly capable and committed colleagues over the years. Xbrane and the people here will always mean a great deal to me, and I look forward to following the company's continued development," says Siavash Bashiri, COO & Head of Biosimilars.

Contacts

Martin Åmark, CEO
E: martin.amark@xbrane.com

Jane Benyamin, CFO/IR
E: jane.benyamin@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Hagastaden, Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

This information is information that Xbrane Biopharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-26 11:20 CET.

Attachments

Xbrane Biopharma AB (publ) announces that Siavash Bashiri will leave his role as COO & Head of Biosimilars